2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid

A synthetic small molecule and experimental compound, 2-amino-3-(5-tert-butyl‑3‑(phosphonomethoxy)‑4‑isoxazolyl)propionic acid (commonly known as ATPO), is a structural analog of amino acids in the isoxazole class. It acts primarily as a competitive antagonist at AMPA-type ionotropic glutamate receptors (GluR1–GluR4), with weak partial agonist activity at certain kainate receptor subtypes such as GluR5 and GluR5/KA2. ATPO inhibits AMPA receptor-mediated currents in recombinant systems with micromolar affinity, showing selectivity for AMPA over NMDA or most kainate receptors. The compound has been used experimentally to probe glutamatergic neurotransmission but has not advanced to clinical development or approval[1][5][9].

Other names

(S)-2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)isoxazol-4-yl)propanoic acid(2S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid252930–37–3